Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of ($1.02), $0.55 worse than the analyst estimate of ($0.47).

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.